• Home
  • News
  • Calendar
  • About DF/HCC
  • Membership
  • Visitor Center

DF/HCC News

    DF/HCC Nodal Awards announced

    DF/HCC offers a multitude of funding opportunities to its members to encourage and enhance the collaborative spirit of research within the Harvard medical community

    Success of two DF/HCC SPOREs prompts renewals

    The DF/HCC Lung SPORE, led by Bruce Johnson, MD (DFCI) (left), and the Multiple Myeloma SPORE, led by Kenneth Anderson, MD (DFCI) (right), have each been highly successful in creating cohesion in their respective research programs, sparking new RO1, PO1, and DOD grants, fostering innovative ideas in cancer research, and advancing the careers of junior investigators

    DNA Resource Core

    The DNA Resource Core provides DNA sequencing services and sequence verified plasmid constructs

    Breast cancer specialist Paula Ryan and basic scientist Leif Ellisen, of MGH, are co-investigators on a phase II trial of cisplatin for triple negative breast cancer.
    Divide-and-conquer strategy drives breast cancer breakthroughs

    Pulling a page from ancient Rome’s military handbook, investigators in the DF/HCC Breast Cancer Program are deploying a divide-and-conquer strategy in the battle against breast cancer

    HER2+ breast cancer cells transfected with siRNAs are grown in the presence or absence of Herceptin for four days. Then cell viability and number are measured.
    siRNA knockdowns turn up intriguing HER2 targets

    At best, only 20 to 30 percent of women with HER2-positive breast cancer respond to trastuzumab

    Fusion of renal carcinoma and DCs stained for Cytokeratin (red) and CD86 (blue) 100x.
    Fusion vaccine plus surgery may prove potent combination in renal cell cancer

    Renal cell cancer (RCC) is a life-threatening malignancy considered incurable in the metastatic setting

    Breakefield awarded $5.8 million to study tumors

    DF/HCC member Xandra Breakefield, PhD (MGH) will receive approximately $5.8 million in total costs over five years to study the genetic and cellular factors contributing to the formation and progression of benign tumors in the nervous system

Displaying results 134 to 140 out of 208